Last $0.48 USD
Change Today +0.12 / 33.33%
Volume 100.0
CRYO On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

american cryostem corp (CRYO) Snapshot

Open
$0.48
Previous Close
$0.36
Day High
$0.48
Day Low
$0.48
52 Week High
04/25/14 - $1.25
52 Week Low
09/8/14 - $0.04
Market Cap
15.8M
Average Volume 10 Days
714.9
EPS TTM
--
Shares Outstanding
32.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMERICAN CRYOSTEM CORP (CRYO)

Related News

No related news articles were found.

american cryostem corp (CRYO) Related Businessweek News

No Related Businessweek News Found

american cryostem corp (CRYO) Details

American CryoStem Corporation develops, markets, and licenses patented adipose tissue-based cellular technologies, bio-materials, and related proprietary services. It primarily focuses on clinical processing, commercial bio-banking, and application development for adipose tissue and adipose-derived stem cells. The company’s products include CELLECT validated collection, transportation, and storage system, which is a clinical solution for physicians to collect and deliver adipose tissue samples utilizing proprietary and patent pending methods and materials; ATGRAFT adipose tissue storage service, a clinical fat storage solution allowing physicians to provide their patients with various tissue/stem cell storage options; and ATCELL adipose derived stem cells. It also offers ACSelerat cell culture media products in various versions for growing human stromal cells. Through its ACS Laboratories division, the company manufactures, sells, and licenses patented and patent pending cellular, cell culture, processing, and testing products to professional, institutional, and commercial clients. In addition, it provides contract manufacturing services to physicians and other medical professionals that perform tissue transfer and other cellular therapy services, as well as offers professional services, including sterility, viability, cellular density, and growth assay analysis. The company is headquartered in Eatontown, New Jersey. American CryoStem Corporation is a subsidiary of ACS Global, Inc.

6 Employees
Last Reported Date: 01/14/14

american cryostem corp (CRYO) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $36.8K
Chief Operating Officer, Treasurer, Secretary...
Total Annual Compensation: $27.9K
Compensation as of Fiscal Year 2013.

american cryostem corp (CRYO) Key Developments

American Cryostem Corporation announced delayed 10-Q filing

On 08/14/2014, American Cryostem Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

American CryoStem Corporation Enters into Definitive Term Sheet with Health Innovative Technology Corporation Limited

American CryoStem Corporation announced that it has made a major step in establishing a global footprint for its cellular technology and laboratory processing platform by entering into an agreement to license its ATGRAFT adipose tissue (fat) processing and storage technologies with Health Innovative Technology Corporation Limited (HIT). HIT currently operates a cellular processing and banking platform and a chain of medical centers, offering comprehensive healthcare solutions to clients in Hong Kong. American CryoStem has licensed to HIT the exclusive rights to utilize the company's Standard Operating Procedures (SOP's) to create and market the company's ATGRAFT tissue storage service in Hong Kong. The financial terms call for annual minimum licensing payments as well as additional royalty payments based on gross revenue. HIT will also purchase CRYO's ACSelerate storage media and other products necessary for clinical collection, processing and storage of Adipose Tissue. Upon execution CRYO received the initial payment of the minimum annual licensing fee with the balance of first year licensing payments due prior to full commercial launch of the ATGRAFT service in Hong Kong. The formal licensing agreement is scheduled for finalization within 90 days.

American CryoStem Corporation Announces Agreement with UHV Technologies, Inc. for Cancer Research Utilizing ATCELL

American CryoStem Corporation announced that the company has entered into initial agreements with the nanoRANCH Division of UHV Technologies Inc. for the development of methods for the delivery of therapeutics and drugs focused upon cancer treatments utilizing adipose derived adult stem cells. The Company will be working with Dan Dimitrijevich, PhD to create new treatment delivery methods utilizing a combination of nanoRANCH unique technology and CRYO's clinically processed ATCELLs(TM). The company's research collaboration into cancer research and cancer related applications utilizing CRYO's clinically processed ATCELL(TM) products further expands relationships and potential applications to treat a wide range of diseases in the growing regenerative and therapeutic cellular therapy markets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRYO:US $0.48 USD +0.12

CRYO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRYO.
View Industry Companies
 

Industry Analysis

CRYO

Industry Average

Valuation CRYO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 149.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 139.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMERICAN CRYOSTEM CORP, please visit www.americancryostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.